Acadia Pharma (ACAD) Misses Q4 EPS by 1c; Offers FY23 Revenue Guidance
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $22.60 +2.31%
EPS Growth %: -62.5%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: -62.5%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of ($0.26), $0.01 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $136.5 million versus the consensus estimate of $134.23 million.
GUIDANCE:
Acadia Pharma sees FY2023 Nuplazid sales of $520-530 million, versus the consensus of $569 million.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Bernstein SocGen Group Reiterates Outperform Rating on Hermes International (RMS:FP) (HESAY) after cautious commentary
- BofA lists top 5 themes driving next $1tn in incremental semi sales
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
